A cardiotonic steroid with diverse biological activities
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Telocinobufagin

Item No. 27981

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
3β,5β,14-trihydroxy-bufa-20,22-dienolide
CAS Number
472-26-4
Synonyms
  • NSC 90782
  • NSC 119989
  • Telobufotoxin
  • Telocinobufogenin
Molecular Formula
C24H34O5
Formula Weight
402.5
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
Chloroform: slightly, heatedMethanol: slightly soluble
λmax
301 nm
SMILES
O[C@H]1CC[C@@]2(C)[C@@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@]3(O)CC[C@@H]4C5=COC(C=C5)=O)(O)C1
InChi Code
InChI=1S/C24H34O5/c1-21-9-5-16(25)13-23(21,27)11-7-19-18(21)6-10-22(2)17(8-12-24(19,22)28)15-3-4-20(26)29-14-15/h3-4,14,16-19,25,27-28H,5-13H2,1-2H3/t16-,17+,18-,19+,21+,22+,23-,24-/m0/s1
InChi Key
PBSOJKPTQWWJJD-ZBDZJSKLSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $41

    Add

    5 mg

    $178

    Add

    10 mg

    $312

    Add

    25 mg

    $680

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Telocinobufagin is a cardiotonic steroid that has been found in skin secretions of the toad B. rubescens and has diverse biological activities.1,2,3,4 It inhibits human kidney Na+/K+-ATPase with an IC50 value of 44.2 nM.3 Telocinobufagin (9.9 μg/ml) increases contraction force in isolated frog ventricle strips by 30.2%.2 It is cytotoxic to HL-60, HCT8, SF295, MDA-MB-435 cancer cells and human peripheral blood lymphocytes (IC50s = 0.06, 0.06, 0.03, 0.11, and 0.05 μM, respectively).4 Telocinobufagin is also active against E. coli and S. aureus (MICs = 64 and 128 μg/ml, respectively).2

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pavlovic, D. The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin. Pract. 128(1-2), 11-21 (2014).

    2. Cunha Filho, G.A., Schwartz, C.A., Resck, I.S., et al. Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens. Toxicon. 45(6), 777-782 (2005).

    3. Touza, N.A., Pôças, E.S., Quintas, L.E.M., et al. Inhibitory effect of combinations of digoxin and endogenous cardiotonic steroids on Na+/K+-ATPase activity in human kidney membrane preparation. Life Sci. 88(1-2), 39-42 (2011).

    4. G.A., C.-F., Resck, I.S., Cavalcanti, B.C., et al. Cytotoxic profile of natural and some modified bufadienolides from toad Rhinella schneideri parotoid gland secretion. Toxicon. 56(3), 339-348 (2010).